Chuah: Efficacy of Early Treatment with Favipiravir on Disease Progression among High Risk COVID-19 Patients: A Randomized, Open-Label Clinical Trial

Efficacy of Early Treatment with Favipiravir on Disease Progression among High Risk COVID-19 Patients: A Randomized, Open-Label Clinical Trial

Chuah et al., Clinical Infectious Diseases, doi:10.1093/cid/ciab962

Chuah et al., Efficacy of Early Treatment with Favipiravir on Disease Progression among High Risk COVID-19 Patients: A.., Clinical Infectious Diseases, doi:10.1093/cid/ciab962

Nov 2021 Source PDF

Twitter
Facebook

All Studies Meta

RCT 500 hospitalized patients in Malaysia, showing no significant differences with favipiravir treatment.

Important missing comments or errors? Let us know.

risk of death, 1154.0% higher, RR 12.54, p = 0.08, treatment 5 of 250 (2.0%), control 0 of 250 (0.0%), odds ratio converted to relative risk, continuity correction due to zero event (with reciprocal of the contrasting arm).

risk of mechanical ventilation, 19.5% higher, RR 1.20, p = 0.76, treatment 6 of 250 (2.4%), control 5 of 250 (2.0%), odds ratio converted to relative risk.

risk of ICU admission, 8.5% higher, RR 1.09, p = 0.84, treatment 13 of 250 (5.2%), control 12 of 250 (4.8%), odds ratio converted to relative risk.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Chuah et al., 19 Nov 2021, Randomized Controlled Trial, Malaysia, peer-reviewed, 18 authors.

All Studies Meta Analysis Submit Updates or Corrections

This Paper Favipiravir All

Abstract: Efficacy of Early Treatment with Favipiravir on Disease Progression among High Risk COVID-19 Patients: A Randomized, Open-Label Clinical Trial Chuan Huan, Chuah1, Ting Soo, Chow1, Chee Peng, Hor2,3, Joo Thye, Cheng4, Hong Bee, Ker5, Heng Gee, Lee6, Kok Soon, Lee7, Noridah, Nordin8, Tiang Koi, Ng9, t Adnan13, Noorlina, Nordin14, Tze Yuan, Tee15, Su Miin, Ong16, Suresh Kumar, us cr ip Chidambaram17,§, Mahiran, Mustafa8, §, for the Malaysian Favipiravir Study Group 1. Department of Medicine, Penang General Hospital, Penang, Malaysia 2. Department of Medicine, Kepala Batas Hospital, Penang, Malaysia an 3. Clinical Research Centre, Seberang Jaya Hospital, Penang, Malaysia 4. Department of Medicine, Seberang Jaya Hospital, Penang, Malaysia M 5. Department of Medicine, Raja Permaisuri Bainun Hospital, Perak, Malaysia 6. Department of Medicine, Queen Elizabeth Hospital, Sabah, Malaysia pt e Malaysia d 7. Department of Medicine, Enche' Besar Hajjah Khalsom Hospital, Johor, 8. Department of Medicine, Raja Perempuan Zainab II Hospital, Kelantan, ce Malaysia Ac 9. Department of Medicine, Tuanku Ja'afar Hospital, Negeri Sembilan, Malaysia 10. Department of Medicine, Sultanah Aminah Hospital, Johor, Malaysia 11. Department of Medicine, Melaka Hospital, Malacca, Malaysia 12. Department of Medicine, Tuanku Fauziah Hospital, Perlis, Malaysia 13. Department of Medicine, Sultanah Nur Zahirah Hospital, Terrengganu, Malaysia 14. Department of Medicine, Tengku Ampuan Afzan Hospital, Pahang, Malaysia 15. Department of Medicine, Tawau Hospital, Sabah, Malaysia © The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. Masliza, Zaid10, Nor Zaila, Zaidan11, Suhaila, Abdul Wahab12, Nurul Ashikin, 16. Institute for Clinical Research, National Institute of Health, Malaysia 17. Department of Medicine, Sungai Buloh Hospital, Selangor, Malaysia § Equal contributors t us cr ip Dr Chuan Huan, Chuah Email: chchuah7@yahoo.com Department of Medicine, Penang General Hospital, George Town, Penang, M an Malaysia. Summary: Role of favipiravir remains uncertain in COVID-19. Early treatment with d five days oral favipiravir did not prevent disease progression from non-hypoxia to pt e hypoxia in high-risk patients. No beneficial effects were observed in preventing Ac ce mechanical ventilation, ICU admission, and in-hospital mortality. 2 CORRESPONDING AUTHOR ABSTRACT Background Role of favipiravir in preventing disease progression in COVID-19 remains uncertain. We aimed to determine its effect in preventing disease progression from non-hypoxia us cr ip t Study design This was an open-label, randomized clinical trial conducted at 14 public hospitals across Malaysia from February to June 2021 among 500 symptomatic, RT-PCR confirmed COVID-19 patients, aged ≥50 years with ≥1 co-morbidity, and hospitalized an within first 7 days of illness. Patients were randomized on 1:1 ratio to favipiravir plus M standard care or standard care alone. Favipiravir was administered at 1800mg twicedaily on day 1 followed by 800mg twice-daily until day 5. The primary endpoint was d rate of..

Late treatment
is less effective

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit